Skip to main content
The University of Arizona Wordmark Line Logo White
Stories & Features Announcements Calendar Leadership Updates Event Planning Room Scheduling Café Bolo Directories IT Support Classroom Support Planning & Facilities
The University of Arizona Health Sciences | Home
Subscribe
Support
home home

Main navigation

  • Overview Senior Leadership Academic Leadership Executive Leadership Annual Report Mission, Values, History Support
  • Overview College of Health Sciences College of Medicine – Phoenix College of Medicine – Tucson College of Nursing Mel and Enid Zuckerman College of Public Health R. Ken Coit College of Pharmacy
  • Research Administration Research Awards and Grants
  • Clinical
  • Overview Community Engagement Alliance Corporate and Community Relations Health and Humanities Rural Health Community Events Student Engagement and Career Advancement
  • Overview Aegis Consortium All of Us Research Program Arizona Area Health Education Centers Arizona Simulation Technology & Education Center Asthma & Airway Disease Research Center Center for Accelerated Biomedical Innovation Center for Advanced Molecular & Immunological Therapies Center for Biomedical Informatics & Biostatistics Center for Disparities in Diabetes, Obesity & Metabolism Center for Innovation in Brain Science Center for Sleep, Circadian & Neuroscience Research Clinical & Translational Sciences Research Center Comprehensive Center for Pain & Addiction Health Sciences SensorLab One Health University of Arizona Cancer Center
  • All News Stories Videos The Healthy Dose Blog News Releases In The Media Media Resources Office of Communications
  1. Home
  2. Node

Behavioral Sleep Medicine: Training in Sleep and Aging

Read more about Behavioral Sleep Medicine: Training in Sleep and Aging

Patterns of Survivors' Recovery Trajectories in the ICECAP trial POST-ICECAP

Read more about Patterns of Survivors' Recovery Trajectories in the ICECAP trial POST-ICECAP

COG Project: Everychild (Apec14b1) Supplemental Per-case Reimbursement

Read more about COG Project: Everychild (Apec14b1) Supplemental Per-case Reimbursement

COG Per-case Reimbursement St. Baldrick's Supplement

Read more about COG Per-case Reimbursement St. Baldrick's Supplement

COG Amazon Supplemental Payments

Read more about COG Amazon Supplemental Payments

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

Read more about A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated

Read more about A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul

Read more about A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul

A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery

Read more about A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery

A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension

Read more about A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • Next › Next page
  • Last » Last page
Subscribe to
The University of Arizona Health Sciences | Home

Health Sciences

  • About
  • Academics
  • Research
  • Centers and Programs
  • Clinical Care
  • Outreach
  • Initiatives

News

  • Stories
  • Healthy Dose Blog
  • News Releases
  • In The Media
  • Media Resources
  • Videos

Internal Resources

  • Stories & Features
  • Announcements
  • Calendar
  • Leadership Updates
  • Honors and Awards
  • Event Planning
  • Room Scheduling
  • Café Bolo
  • El Mirador Project
  • IT Support
  • Classroom Support
  • Planning and Facilities
  • Photo Galleries
  • Directories

Connect

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • X, formerly Twitter

We respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples. Today, Arizona is home to 22 federally recognized tribes, with Tucson being home to the O’odham and the Yaqui. The university strives to build sustainable relationships with sovereign Native Nations and Indigenous communities through education offerings, partnerships, and community service.


University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.